Khan, Omar
Giles, Josephine R.
McDonald, Sierra
Manne, Sasikanth
Ngiow, Shin Foong
Patel, Kunal P.
Werner, Michael T.
Huang, Alexander C.
Alexander, Katherine A.
Wu, Jennifer E.
Attanasio, John
Yan, Patrick
George, Sangeeth M.
Bengsch, Bertram
Staupe, Ryan P.
Donahue, Greg
Xu, Wei
Amaravadi, Ravi K.
Xu, Xiaowei
Karakousis, Giorgos C.
Mitchell, Tara C.
Schuchter, Lynn M.
Kaye, Jonathan
Berger, Shelley L.
Wherry, E. John
Article History
Received: 4 June 2018
Accepted: 30 May 2019
First Online: 17 June 2019
Competing interests
: O.K. is an employee of Arsenal Biosciences. R.K.A. serves as a consultant for Sprint Biosciences, Immunacell and Array Pharmaceuticals and is a founder of Pinpoint Therapeutics. T.C.M. is an advisor to and/or receives honoraria from Aduro, Array, BMS, Incyte, Merck, and Regeneron. S.L.B. receives research funding from Celgene. E.J.W. receives honoraria, consulting fees and/or research support from BMS, Celgene, Dynavax, Eli Lilly, Elstar, Merck, MedImmune, Pieris, Roche, Surface Oncology, and KyMab. E.J.W. is a founder of Arsenal Biosciences. E.J.W. has a patent licensing agreement for the PD-1 pathway.